亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Prospective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks

医学 背景(考古学) 动静脉瘘 血液透析 观察研究 前瞻性队列研究 外科 内科学 生物 古生物学
作者
Anukul Ghimire,Anita Lloyd,Susan K. Szigety,José Luis Merino,Karim Alibhai,Gerrit B. Winkelaar,Robert R. Quinn,Marcello Tonelli
出处
期刊:Kidney360 [American Society of Nephrology (ASN)]
标识
DOI:10.34067/kid.0000000650
摘要

Background: Many patients with newly created arteriovenous fistulas (AVF) may die before the AVF is needed for hemodialysis. However, formal competing risks frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary non-function and to describe long-term patency using a competing risk framework. Methods: We did a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary non-function. Secondary outcomes included loss of primary-patency, loss of assisted primary-patency, and loss of secondary functional-patency. Results were presented using icon-array plots to form the basis for future decision aids. Results: Participants were 63.0% male with mean age 62.3 years and median follow-up of 18.5 months (range 0.02-180 months). Of 257 participants, 50 could not be assessed for function or primary non-function, usually due to death. Of the remaining 207, 102 (49.3%) had primary non-function, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of competing risks led to biased results from Kaplan-Meier analyses of lost patency. When accounting for competing risks, loss of primary-patency among AVF with established function was 36.6%, 65.5% and 66.2%, at 1y, 3y and 5y respectively. Conclusions: Only 55% of fistulas were ultimately used for hemodialysis when accounting for competing risks and primary non-function. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈欣瑶完成签到 ,获得积分10
13秒前
答辩完成签到 ,获得积分10
13秒前
NexusExplorer应助读书的时候采纳,获得30
16秒前
25秒前
科研通AI2S应助琪琪采纳,获得10
26秒前
月落无痕97完成签到 ,获得积分0
27秒前
xiuxiuzhang完成签到 ,获得积分10
29秒前
JamesPei应助世界需要我采纳,获得10
33秒前
长言完成签到 ,获得积分10
37秒前
41秒前
徐志豪发布了新的文献求助10
43秒前
圈哥完成签到 ,获得积分10
44秒前
46秒前
得分发布了新的文献求助10
53秒前
科研通AI6应助科研通管家采纳,获得10
55秒前
Akim应助科研通管家采纳,获得10
56秒前
科研通AI6应助科研通管家采纳,获得10
56秒前
Akim应助科研通管家采纳,获得10
56秒前
CodeCraft应助科研通管家采纳,获得10
56秒前
1分钟前
传奇3应助G1采纳,获得10
1分钟前
FashionBoy应助读书的时候采纳,获得10
1分钟前
田様应助Re采纳,获得10
1分钟前
yhl完成签到 ,获得积分10
1分钟前
可一可再完成签到 ,获得积分10
1分钟前
Matberry完成签到 ,获得积分10
1分钟前
852应助爱做实验的泡利采纳,获得10
1分钟前
碧蓝巧荷完成签到 ,获得积分10
1分钟前
33333完成签到 ,获得积分10
1分钟前
chongziccc完成签到 ,获得积分10
1分钟前
1分钟前
张维发布了新的文献求助10
1分钟前
冷风完成签到 ,获得积分10
1分钟前
无花果应助读书的时候采纳,获得30
1分钟前
1分钟前
Lemon完成签到 ,获得积分10
1分钟前
张维完成签到,获得积分10
1分钟前
炙热的夜雪完成签到 ,获得积分10
1分钟前
Gryff完成签到 ,获得积分10
1分钟前
安静含卉发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Introduction to strong mixing conditions volume 1-3 5000
Human Embryology and Developmental Biology 7th Edition 2000
The Developing Human: Clinically Oriented Embryology 12th Edition 2000
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 2000
从k到英国情人 1500
„Semitische Wissenschaften“? 1110
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5739130
求助须知:如何正确求助?哪些是违规求助? 5384111
关于积分的说明 15339445
捐赠科研通 4881845
什么是DOI,文献DOI怎么找? 2623962
邀请新用户注册赠送积分活动 1572643
关于科研通互助平台的介绍 1529394